ClinicalTrials.gg
CompletedNCT04551911Updated May 28, 2024Results posted

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Phase 2 interventional study of Rayaldee and Placebo in COVID-19, Coronavirus and SARS-CoV2 Infection, sponsored by OPKO Health, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
516th of 1,321
171 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
674th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 516th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 674th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.

03

Conditions studied

  • COVID-19
  • Coronavirus
  • SARS-CoV2 Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age
  2. Confirmed within the past 3 days to have SARS-CoV-2 infection as evidenced by a positive nasopharyngeal swab test using RT-PCR or any substitutable FDA-authorized diagnostic test
  3. Confirmed to have only mild or moderate COVID-19 based on the first of the patient reported scores obtained during screening which meets the criterion a FLU-PRO Plus© score of ≥ 1.5 for each of the chest/respiratory and body/systemic domains, and the absence of clinical signs indicative of more severe disease (eg, oxygen saturation \< 94% on room air or respiration rate > 30 bpm)
  4. Represents on self-assessment that the current COVID-19 symptoms are not consistent with usual health and that they are the same or worse than on the previous day
  5. Willing to limit the use of vitamin D therapies or supplements except for normally fortified food products (eg, milk) during the course of the 6-week study
  6. Must demonstrate the ability to comply with all study requirements
  7. Must be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation.

Exclusion criteria

Exclusion Criteria:

  1. Clinical signs indicative of severe or critical COVID-19 disease (eg, oxygen saturation \< 94% on room air or respiration rate > 30 bpm)
  2. Pregnant or lactating women who are breastfeeding
  3. Use of systemic medications in the last six months
  4. Recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, hypercalciuria and/or hypercalcemia
  5. History of a chronic granuloma-forming disease (eg, sarcoidosis)
  6. History of tuberculosis or histoplasmosis
  7. History of chronic liver disease
  8. History (previous 12 months) of cardiac event indicative of chronic cardiovascular diseases including congestive heart failure, poorly controlled hypertension and arrhythmias
  9. History in the past five years of multiple myeloma or carcinoma of the breast, lung or prostate
  10. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of vitamin D or 25-hydroxyvitamin D (25D) (eg, small bowel resection, history of Crohn's disease or ulcerative colitis)
  11. Ongoing treatment with thiazide diuretics
  12. History of hyperphosphatemia, hyperuricemia and gout
  13. Renal impairment measured as \< 15 mL/min/1.73m² on serum creatinine in the last three months
  14. Serum calcium ≥9.8 mg/dL in the last three months
  15. Evidence of existing or impending dehydration
  16. Known or suspected to have to any of the constituents of the study drug
  17. Currently participating in, or have participated in, an interventional/ study within 30 days prior to study screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Rayaldee

    Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.

    Drug: Rayaldee

  • Placebo comparator
    Placebo

    Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.

    Drug: Placebo

Interventions

  • 30 mcg calcifediol Extended-Release (ER) Capsule

    Also known as: CTAP101 Capsule

  • DrugPlacebo

    0 mcg calcifediol Extended-Release (ER) Capsule

06

What researchers measure

Primary outcomes

  1. Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).

    Number and percentage of subjects with serum total 25-hydroxyvitamin D attained at or above 50 ng/mL at Visit 3 (Day 14)

    Time frame: 14 days

  2. Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.

    The FLU- PRO Plus© questionnaire was specifically designed and validated to evaluate in clinical trials the presence, severity and duration of symptoms associated with viral infections. It contains 32 items (eg, felt hot, sweating, headache), grouped into 6 domains, that provide a comprehensive evaluation of such symptoms, using 5-point scales (values ranging from 0 to 4) with higher scores indicating worse symptoms. The number of days to resolution of the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a reduction in the aggregate symptom score recorded on Day 0 (prior to study drug initiation) by the FLU-PRO Plus© questionnaire to or below 5 for a minimum of three consecutive days. Flu-PRO Plus© was created and supplied by Dr. John Powers and Leidos Biomedical, and the National Institute for Allergy and Infectious Diseases (NIAID).

    Time frame: 42 days

Secondary outcomes

  1. Time to Resolution of COVID-19 Five Aggregated Symptoms

    The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), as measured by the FLU-PRO Plus© questionnaire, with resolution defined as the first aggregate symptom score of ≤5 which is maintained for a minimum of three consecutive days, with no individual symptom score \>1

    Time frame: 42 days

  2. Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10

    Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10

    Time frame: 10 days

  3. Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10

    Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10. Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates.

    Time frame: 10 days

  4. Number of Participants With Emergency Room/Urgent Care Visits

    Number and percentage of subjects with emergency room/urgent care visits

    Time frame: 42 days

  5. Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)

    Number and percentage of subjects with oxygen saturation below 94% (without supplemental oxygen)

    Time frame: 42 days

  6. Number of Participants With Hospitalizations

    Number and percentage of subjects with hospitalization

    Time frame: 42 days

  7. Number of Participants With the Requirement for Mechanical Ventilation

    Number and percentage of subjects requiring mechanical ventilation

    Time frame: 42 days

  8. Number of Participant Deaths

    Number and percentage of subjects who died

    Time frame: 42 days

  9. Severity of COVID-19 Illness as Evidenced by Quality of Life Measures Using the FLU-PRO Plus Questionnaire

    Quality-of-Life (QOL) responses are based on the number of non-missing observations within individual QOL question and visit. Comparisons to baseline are assessed only for subjects who were at risk for improvement. Percentages for the comparisons to baseline are based on the number at-risk for improvement.

    Time frame: 14 days

  10. Resolution of Symptoms Based on FLU-PRO Plus© COVID-19 Five Symptom Aggregate Score Based on Serum 25D Level Over the Treatment Period

    Clinical course of COVID-19 as a function of Serum Total 25-hydroxyvitamin D concentrations of \<50 ng/mL, 50 to 100 ng/mL and \>100 ng/mL at Day 14, defined as the proportion of subjects in each treatment group with a total score of ≤5 for the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) using the FLU-PRO Plus© questionnaire. Results were similar for comparisons between treatment groups on Days 7, 14, 21 and 28, and only data for Day 14 is presented.

    Time frame: 14 days

07

Results

Posted May 28, 2024
Limitations and caveats
A caveat in the analysis is the variability of 25D at baseline. The study is also limited by timing differences between the onset of symptoms and diagnosis of COVID-19, and between COVID-19 diagnosis and the initiation of treatment among participants.

Participant flow

Participant flow — Overall Study
MilestoneRayaldeePlacebo
Started8586
Completed7071
Not completed1515
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject1010
Withdrew: Did not receive the study drug34

Outcome measures

PrimaryConcentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).

Number and percentage of subjects with serum total 25-hydroxyvitamin D attained at or above 50 ng/mL at Visit 3 (Day 14)

Time frame:
14 days
Reported as:
Count of participants · Participants
Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).
ParticipantsRayaldeePlacebo
Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).5110
PrimaryResolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.

The FLU- PRO Plus© questionnaire was specifically designed and validated to evaluate in clinical trials the presence, severity and duration of symptoms associated with viral infections. It contains 32 items (eg, felt hot, sweating, headache), grouped into 6 domains, that provide a comprehensive evaluation of such symptoms, using 5-point scales (values ranging from 0 to 4) with higher scores indicating worse symptoms. The number of days to resolution of the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a reduction in the aggregate symptom score recorded on Day 0 (prior to study drug initiation) by the FLU-PRO Plus© questionnaire to or below 5 for a minimum of three consecutive days. Flu-PRO Plus© was created and supplied by Dr. John Powers and Leidos Biomedical, and the National Institute for Allergy and Infectious Diseases (NIAID).

Time frame:
42 days
Reported as:
Mean · days
Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.
daysRayaldeePlacebo
Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.9.8 ± 8.1510.8 ± 9.54
SecondaryTime to Resolution of COVID-19 Five Aggregated Symptoms

The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), as measured by the FLU-PRO Plus© questionnaire, with resolution defined as the first aggregate symptom score of ≤5 which is maintained for a minimum of three consecutive days, with no individual symptom score \>1

Time frame:
42 days
Reported as:
Mean · days
Time to Resolution of COVID-19 Five Aggregated Symptoms
daysRayaldeePlacebo
Time to Resolution of COVID-19 Five Aggregated Symptoms12.0 ± 8.7012.6 ± 9.09
SecondaryNumber of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10

Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10

Time frame:
10 days
Reported as:
Number · Number of participants
Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10
Number of participantsRayaldeePlacebo
Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 103841
SecondaryProportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10

Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10. Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates.

Time frame:
10 days
Reported as:
Number · Proportion
Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10
ProportionRayaldeePlacebo
Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 100.6180.592
Statistical analysis
  • Rayaldee vs Placebo · Regression, Logistic · p = 0.7856Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates
SecondaryNumber of Participants With Emergency Room/Urgent Care Visits

Number and percentage of subjects with emergency room/urgent care visits

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participants With Emergency Room/Urgent Care Visits
ParticipantsRayaldeePlacebo
Number of Participants With Emergency Room/Urgent Care Visits03
SecondaryNumber of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)

Number and percentage of subjects with oxygen saturation below 94% (without supplemental oxygen)

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)
ParticipantsRayaldeePlacebo
Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)01
SecondaryNumber of Participants With Hospitalizations

Number and percentage of subjects with hospitalization

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participants With Hospitalizations
ParticipantsRayaldeePlacebo
Number of Participants With Hospitalizations00
SecondaryNumber of Participants With the Requirement for Mechanical Ventilation

Number and percentage of subjects requiring mechanical ventilation

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participants With the Requirement for Mechanical Ventilation
ParticipantsRayaldeePlacebo
Number of Participants With the Requirement for Mechanical Ventilation00
SecondaryNumber of Participant Deaths

Number and percentage of subjects who died

Time frame:
42 days
Reported as:
Count of participants · Participants
Number of Participant Deaths
ParticipantsRayaldeePlacebo
Number of Participant Deaths00
SecondarySeverity of COVID-19 Illness as Evidenced by Quality of Life Measures Using the FLU-PRO Plus Questionnaire

Quality-of-Life (QOL) responses are based on the number of non-missing observations within individual QOL question and visit. Comparisons to baseline are assessed only for subjects who were at risk for improvement. Percentages for the comparisons to baseline are based on the number at-risk for improvement.

Time frame:
14 days
Reported as:
Count of participants · Participants
Severity of COVID-19 Illness as Evidenced by Quality of Life Measures Using the FLU-PRO Plus Questionnaire
ParticipantsRayaldeePlacebo
Overall, how severe were your infection symptoms today? — Improved compared to baseline4748
Overall, how severe were your infection symptoms today? — Worsened compared to baseline11
Overall, how severe were your infection symptoms today? — No charge from baseline57
Overall, how severe were your infection symptoms today? — Missing1210
Overall, how were your infection symptoms today compared to yesterday? — Improved compared to baseline4550
Overall, how were your infection symptoms today compared to yesterday? — Worsened compared to baseline01
Overall, how were your infection symptoms today compared to yesterday? — No charge from baseline87
Overall, how were your infection symptoms today compared to yesterday? — Missing1210
How much did your infection symptoms interfere with your usual activities today? — Improved compared to baseline4852
How much did your infection symptoms interfere with your usual activities today? — Worsened compared to baseline10
How much did your infection symptoms interfere with your usual activities today? — No charge from baseline45
How much did your infection symptoms interfere with your usual activities today? — Missing1210
Have you returned to your usual activities today? — Improved compared to baseline2634
Have you returned to your usual activities today? — Worsened compared to baseline00
Have you returned to your usual activities today? — No charge from baseline2624
Have you returned to your usual activities today? — Missing1210
In general, how would you rate your physical health today? — Improved compared to baseline4847
In general, how would you rate your physical health today? — Worsened compared to baseline01
In general, how would you rate your physical health today? — No charge from baseline510
In general, how would you rate your physical health today? — Missing1211
Have you returned to your usual health today? — Improved compared to baseline1919
Have you returned to your usual health today? — Worsened compared to baseline00
Have you returned to your usual health today? — No charge from baseline3439
Have you returned to your usual health today? — Missing1210
SecondaryResolution of Symptoms Based on FLU-PRO Plus© COVID-19 Five Symptom Aggregate Score Based on Serum 25D Level Over the Treatment Period

Clinical course of COVID-19 as a function of Serum Total 25-hydroxyvitamin D concentrations of \<50 ng/mL, 50 to 100 ng/mL and \>100 ng/mL at Day 14, defined as the proportion of subjects in each treatment group with a total score of ≤5 for the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) using the FLU-PRO Plus© questionnaire. Results were similar for comparisons between treatment groups on Days 7, 14, 21 and 28, and only data for Day 14 is presented.

Time frame:
14 days
Reported as:
Count of participants · Participants
Resolution of Symptoms Based on FLU-PRO Plus© COVID-19 Five Symptom Aggregate Score Based on Serum 25D Level Over the Treatment Period
ParticipantsRayaldeePlacebo
Serum 25D Level <50 ng/mL — Yes438
Serum 25D Level <50 ng/mL — No617
Serum 25D Level 50 - 100 ng/mL — Yes288
Serum 25D Level 50 - 100 ng/mL — No82
Serum 25D Level >100 ng/mL — Yes110
Serum 25D Level >100 ng/mL — No40

Adverse events

Collected over 42 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rayaldee0/80 (0%)3/80 (3.8%)12/80 (15%)
Placebo0/80 (0%)1/80 (1.3%)12/80 (15%)
Most frequent serious events
Most frequent serious events
EventRayaldeePlacebo
COVID-19 pneumoniaInfections and infestations3/800/80
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/800/80
COVID-19Infections and infestations0/801/80
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRayaldeePlacebo
COVID-19Infections and infestations0/805/80
COVID-19 pneumoniaInfections and infestations3/801/80
Transaminases increasedInvestigations2/800/80
NauseaGastrointestinal disorders2/801/80
HeadacheNervous system disorders1/802/80
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/800/80
Herpes zosterInfections and infestations1/800/80
SinusitisInfections and infestations0/801/80
Electrocardiogram ST-T segment abnormalInvestigations1/801/80
Blood parathyroid hormone increasedInvestigations1/800/80

Baseline characteristics

Analysis is for the per protocol population, subjects who had a baseline aggregate five symptom score of \>5 and did not have a major protocol deviation prior to resolution.

Age, Continuous
Age, Continuous(years)RayaldeePlaceboTotal
Mean42.1 ± 14.1343.8 ± 14.3243.0 ± 14.20
Sex: Female, Male
Sex: Female, Male(Participants)RayaldeePlaceboTotal
Female384179
Male272855
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RayaldeePlaceboTotal
Hispanic or Latino5556111
Not Hispanic or Latino101323
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RayaldeePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7310
White5865123
More than one race000
Unknown or Not Reported011
Height
Height(cm)RayaldeePlaceboTotal
Mean167.91 ± 9.375167.34 ± 8.747167.62 ± 9.027
Weight
Weight(kg)RayaldeePlaceboTotal
Mean81.05 ± 18.73084.27 ± 18.98582.71 ± 18.860
BMI
BMI(kg/m2)RayaldeePlaceboTotal
Mean28.62 ± 5.52129.99 ± 5.91329.32 ± 5.746
eGFR (glomerular filtration rate)
eGFR (glomerular filtration rate)(mL/min/1.73m^2)RayaldeePlaceboTotal
Mean97.5 ± 16.8998.5 ± 18.6298.0 ± 17.74

2 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • OPKO Investigative Site
    San Francisco, California 94127, United States
  • OPKO Investigative Site
    Miami, Florida 33173, United States
  • OPKO Investigative Site
    Miami, Florida 33185, United States
  • OPKO Investigative Site
    Evanston, Illinois 60201, United States
  • OPKO Investigative Site
    Laurel, Maryland 20723, United States
  • OPKO Investigative Site
    Farmington Hills, Michigan 48334, United States
  • OPKO Investigative Site
    Jackson, Michigan 49201, United States
  • OPKO Investigative Site
    Sterling Heights, Michigan 48312, United States
  • OPKO Investigative Site
    Brookhaven, Mississippi 39601, United States
  • OPKO Investigative Site
    Omaha, Nebraska 68131, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Oct 2021, 11 months.

Results were first posted in May 2024, 2 years 7 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 16, 2020
StartActual
Nov 2, 2020
Primary completionActual
Oct 8, 2021
CompletionActual
Oct 8, 2021
Results first posted
May 28, 2024
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04551911
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Nov 2, 2020
Primary completion
Oct 8, 2021
Completion
Oct 8, 2021
Results posted
May 28, 2024
Last update
May 28, 2024

Study contacts

Akhtar Ashfaq, MD FACP FASN
study director · OPKO Health, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion